EP0404376A2 — Buffered metronidazole compositions for intravaginal treatment of vaginal infections
Assigned to Meda AB · Expires 1990-12-27 · 35y expired
What this patent protects
A composition and method for treatment of bacterial vaginosis and/or trichomoniasis are disclosed. An afflicted vagina is treated with a therapeutically effective amount of a buffered metronidazole composition having a pH in the range of about 3 to about 4.25, preferably about 3.…
USPTO Abstract
A composition and method for treatment of bacterial vaginosis and/or trichomoniasis are disclosed. An afflicted vagina is treated with a therapeutically effective amount of a buffered metronidazole composition having a pH in the range of about 3 to about 4.25, preferably about 3.75 to about 4.25. A preferred such composition comprises metronidazole, a gelled hydrophobic and water-dispersible polymer, such as a polyacrylic acid polymer having a molecular weight in the range of about 1,250,000 to about 4,000,000 daltons, and an aqueous solvent for the metronidazole.
Drugs covered by this patent
- Azelex (AZELAIC ACID) · Leo Pharma As
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.